{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:19:40Z","timestamp":1791206380371,"version":"4.1.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1097\/cco.0b013e3282f9782b","type":"journal-article","created":{"date-parts":[[2010,1,27]],"date-time":"2010-01-27T01:24:54Z","timestamp":1264555494000},"page":"300-306","source":"Crossref","is-referenced-by-count":105,"title":["Renal cell carcinoma"],"prefix":"10.1097","volume":"20","author":[{"given":"Brian I","family":"Rini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W Kimryn","family":"Rathmell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Godley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-11-20210128","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.urology.2006.02.036","article-title":"Racial disparity in outcomes of a clinical trial population with metastatic renal cell carcinoma","volume":"68","author":"Tripathi","year":"2006","journal-title":"Urology"},{"issue":"6","key":"R3-11-20210128","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/j.juro.2006.07.130","article-title":"The epidemiology of renal cell carcinoma","volume":"176","author":"Lipworth","year":"2006","journal-title":"J Urol"},{"key":"R4-11-20210128","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/sj.bjc.6603281","article-title":"Cigarette smoking, von Hippel-Lindau gene mutations and sporadic renal cell carcinoma","volume":"95","author":"van Dijk","year":"2006","journal-title":"Br J Cancer"},{"key":"R5-11-20210128","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/ijc.21398","article-title":"Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC)","volume":"118","author":"Pischon","year":"2006","journal-title":"Int J Cancer"},{"key":"R6-11-20210128","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1002\/ijc.21765","article-title":"Fruits and vegetables and renal cell carcinoma: findings from the European prospective investigation into cancer and nutrition (EPIC)","volume":"118","author":"Weikert","year":"2006","journal-title":"Int J Cancer"},{"key":"R7-11-20210128","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/jama.296.11.1371","article-title":"Long-term fatty fish consumption and renal cell carcinoma incidence in women","volume":"296","author":"Wolk","year":"2006","journal-title":"JAMA"},{"key":"R8-11-20210128","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J Clin Oncol"},{"key":"R9-11-20210128","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.juro.2007.03.106","article-title":"A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy","volume":"178","author":"Lane","year":"2007","journal-title":"J Urol"},{"key":"R10-11-20210128","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/(SICI)1097-0142(19970901)80:5<992::AID-CNCR26>3.0.CO;2-Q","article-title":"TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)","volume":"80","author":"Guinan","year":"1997","journal-title":"Cancer"},{"key":"R11-11-20210128","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2001.19.17.3792","article-title":"Validation of the ucla integrated staging system for patients with renal cell carcinoma","volume":"19","author":"Zisman","year":"2001","journal-title":"J Clin Oncol"},{"key":"R12-11-20210128","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2006.06.1218","article-title":"Multiinstitutional validation of a new renal cancer-specific survival nomogram","volume":"25","author":"Karakiewicz","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"R13-11-20210128","doi-asserted-by":"crossref","first-page":"680s","DOI":"10.1158\/1078-0432.CCR-06-1865","article-title":"The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma","volume":"13","author":"Kaelin","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R14-11-20210128","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/ncb899","article-title":"Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL","volume":"5","author":"Hergovich","year":"2003","journal-title":"Nat Cell Biol"},{"key":"R15-11-20210128","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/ncb1579","article-title":"pVHL and GSK3beta are components of a primary cilium-maintenance signalling network","volume":"9","author":"Thoma","year":"2007","journal-title":"Nat Cell Biol"},{"key":"R16-11-20210128","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.4161\/cc.6.15.4518","article-title":"The VHL tumor suppressor: riding tandem with GSK3beta in primary cilium maintenance","volume":"6","author":"Thoma","year":"2007","journal-title":"Cell Cycle"},{"key":"R17-11-20210128","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.124.3215.269","article-title":"On respiratory impairment in cancer cells","volume":"124","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"R18-11-20210128","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1158\/1078-0432.CCR-06-2510","article-title":"Pseudohypoxic pathways in renal cell carcinoma","volume":"13","author":"Bratslavsky","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R19-11-20210128","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cmet.2006.02.002","article-title":"HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia","volume":"3","author":"Kim","year":"2006","journal-title":"Cell Metab"},{"key":"R20-11-20210128","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10863-007-9081-2","article-title":"HIF-1 mediates the Warburg effect in clear cell renal carcinoma","volume":"39","author":"Semenza","year":"2007","journal-title":"J Bioenerg Biomembr"},{"key":"R21-11-20210128","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10863-007-9088-8","article-title":"Actuality of Warburg's views in our understanding of renal cancer metabolism","volume":"39","author":"Godinot","year":"2007","journal-title":"J Bioenerg Biomembr"},{"key":"R22-11-20210128","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1089\/end.2006.0277","article-title":"Randomized trial of laparoscopic v open nephrectomy","volume":"21","author":"Burgess","year":"2007","journal-title":"J Endourol"},{"key":"R23-11-20210128","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.juro.2006.10.053","article-title":"Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison","volume":"177","author":"Hemal","year":"2007","journal-title":"J Urol"},{"key":"R24-11-20210128","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.juro.2007.03.038","article-title":"Comparison of 1800 laparoscopic and open partial nephrectomies for single renal tumors","volume":"178","author":"Gill","year":"2007","journal-title":"J Urol"},{"key":"R25-11-20210128","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1200\/jco.2007.25.18_suppl.5095","article-title":"Sunitinib therapy for patients (pts) with metastatic renal cell carcinoma (mRCC): updated results of two phase II trials and prognostic factor analysis for survival","volume":"25","author":"Rosenberg","year":"2007","journal-title":"J Clin Oncol"},{"key":"R26-11-20210128","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"R27-11-20210128","doi-asserted-by":"crossref","first-page":"5040","DOI":"10.1200\/jco.2007.25.18_suppl.5040","article-title":"Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC): updated results","volume":"25","author":"Srinivas","year":"2007","journal-title":"J Clin Oncol"},{"key":"R28-11-20210128","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"R29-11-20210128","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1200\/jco.2007.25.18_suppl.5025","article-title":"Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results","volume":"25","author":"Szczylik","year":"2007","journal-title":"J Clin Oncol"},{"key":"R30-11-20210128","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"R31-11-20210128","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1200\/jco.2007.25.18_suppl.5024","article-title":"Sunitinib versus interferon-alfa (IFN-a) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors","volume":"25","author":"Motzer","year":"2007","journal-title":"J Clin Oncol"},{"key":"R32-11-20210128","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jnci\/djk008","article-title":"Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"99","author":"Rini","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"R34-11-20210128","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1200\/jco.2007.25.18_suppl.5023","article-title":"Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis","volume":"25","author":"Bukowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"R35-11-20210128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1200\/jco.2007.25.18_suppl.3","article-title":"A randomized, controlled, double-blind phase III study (Avoren) of bevacizumab\/interferon- {alpha} 2a vs. placebo\/interferon- {alpha} 2a as first-line therapy in metastatic renal cell carcinoma","volume":"25","author":"Escudier","year":"2007","journal-title":"J Clin Oncol"},{"key":"R36-11-20210128","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2007.11.5154","article-title":"Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer","volume":"25","author":"Bukowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"R37-11-20210128","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/jco.2007.25.18_suppl.5027","article-title":"Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): a population pharmacokinetic\/pharmacodynamic (PKPD) approach.","volume":"25","author":"Houk","year":"2007","journal-title":"J Clin Oncol"},{"key":"R38-11-20210128","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.1200\/jco.2007.25.18_suppl.5026","article-title":"A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC).","volume":"25","author":"Amato","year":"2007","journal-title":"J Clin Oncol"},{"key":"R39-11-20210128","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J Clin Oncol"},{"key":"R40-11-20210128","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1200\/JCO.2005.05.179","article-title":"Validation and extension of the Memorial Sloan\u2013Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma","volume":"23","author":"Mekhail","year":"2005","journal-title":"J Clin Oncol"},{"key":"R41-11-20210128","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.juro.2007.08.127","article-title":"Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy","volume":"179","author":"Tamaskar","year":"2008","journal-title":"J Urol"},{"key":"R42-11-20210128","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1200\/jco.2007.25.18_suppl.5038","article-title":"Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients.","volume":"25","author":"Sablin","year":"2007","journal-title":"J Clin Oncol"},{"key":"R43-11-20210128","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.1200\/jco.2007.25.18_suppl.5035","article-title":"Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): updated results and analysis of circulating biomarkers.","volume":"25","author":"George","year":"2007","journal-title":"J Clin Oncol"},{"key":"R44-11-20210128","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1200\/jco.2007.25.18_suppl.5032","article-title":"Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib.","volume":"25","author":"Rini","year":"2007","journal-title":"J Clin Oncol"},{"key":"R45-11-20210128","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1158\/1078-0432.CCR-06-1432","article-title":"Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and\/or metastatic renal cell carcinoma or malignant melanoma","volume":"13","author":"Escudier","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R46-11-20210128","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1200\/JCO.2007.10.8613","article-title":"Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer","volume":"25","author":"Gollob","year":"2007","journal-title":"J Clin Oncol"},{"key":"R47-11-20210128","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1200\/JCO.2007.11.1047","article-title":"Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group","volume":"25","author":"Ryan","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CCO.0b013e3282f9782b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:14:11Z","timestamp":1786040051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001622-200805000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e3282f9782b","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}